Here you can find news about our company and our knowledge discovery platform.
A new study in Nature Reviews Drug Discovery shows late-stage failure rates have doubled since 2013, shifting from scientific to strategic catalysts. Epistemic AI research shows that while global trial initiations have climbed steadily since 2013, the rate of premature terminations in critical late-stage phases has grown at an even faster pace.
ClearView Healthcare Partners announced a $4 million strategic investment in Epistemic AI to advance next-generation biomedical AI platforms. This partnership will integrate Epistemic AI's EpistemicGPT technology across ClearView's service offerings, combining human expertise with AI capabilities to enhance operational efficiency and provide more sophisticated analysis for life sciences organizations.
Epistemic AI unveiled its breakthrough generative AI solution for life science professionals, today at the BIO International Convention. EpistemicGPT is a unique product that addresses the acute market need for immediate access to accurate and reliable biomedical information. It empowers researchers to interact with highly complex data in a way that was unimaginable until now.
EpistemicGPT is the first proprietary multi-agent genAI technology specialized for the Life Sciences. Integrated with a curated network of billions of biomedical information sources through our Epistemic Knowledge Graph to help researchers tease out possible connections between different pieces of data.
Epistemic AI (EAI) welcomes Somnus Scientific as a new customer of its Research Intelligence Platform. Somnus Scientific develops novel micro-sensors that provide real-time measurement of propofol anesthesia and they will use the EAI platform to accelerate their competitive intelligence research and trend analysis.
The Cold Spring Harbor Laboratory (CSHL) has licensed an artificial intelligence platform, developed by Epistemic AI, to accelerate cystic fibrosis (CF)-related discoveries. The platform, which also contains CF-specific resources, will help the lab’s scientists to accelerate their research by providing easy access to publications and clinical trials, and connection to multiple databases.
Epistemic AI (EAI) is pleased to announce that the Cold Spring Harbor Laboratory (CSHL) has licensed its Research Intelligence platform. With support from the Boomer Esiason Foundation (BEF), the EAI platform will help researchers at CSHL to rapidly access documents and data that provide insight into the underlying relationships among diseases, their diagnosis, treatments, and biological functions. The BEF venture philanthropy model was an instrumental component to bring this enhanced capability to CSHL.
In a multi-university study of Myocilin, the authors noted that “to unveil functional relationships in the group of top-100 DEGs (top-50 up- plus top-50 down-regulated genes), we carried out a comprehensive enrichment analysis using Epistemic AI, an artificial intelligence web-based software platform”.
Raquel Atienzar-Aroca, et al. Transgenic Overexpression of Myocilin Leads to Variable Ocular Anterior Segment and Retinal Alterations Associated with Extracellular Matrix Abnormalities in Adult Zebrafish. Int J Mol Sci. 2022 Sep 1;23(17):9989.
Cincinnati Children’s Hospital Medical Center will use Epistemic AI’s platform, a state-of-the-art artificial intelligence (AI) research tool for the life sciences, to augment its research into cystic fibrosis (CF) and other lung conditions. The Boomer Esiason Foundation (BEF) venture philanthropy initiative helped bring this capability to scientists at Cincinnati Children’s.
Epistemic AI (EAI) announced that through its collaboration with the Boomer Esiason Foundation (BEF), and the leadership of Dr. Raouf Amin at Cincinnati Children’s Hospital Medical Center, that the Cincinnati Children’s Division of Pulmonary Medicine will use the EAI platform to augment and accelerate their research in Cystic Fibrosis (CF) and respiratory disease. Epistemic AI will bring AI-powered knowledge discovery to researchers and clinicians in cystic fibrosis.
Epistemic AI has developed what it calls a Knowledge Discovery Platform which is designed to help those working within biomedical research and development. The software uses a mix of machine learning and deep learning algorithms to find existing links within biomedical knowledge, using data from multiple public and private sources.
